Empowering Care,
One Heart at a Time

Elucid is a medical technology company that develops AI to see invisible features of cardiovascular risk.

The company is dedicated to developing a clinical platform to help physicians deliver CCTA-guided personalized care by providing a more precise view of atherosclerosis, the root cause of cardiovascular disease.

Our Mission Statement

Elucid’s mission is to predict and personalize the prevention of heart attacks and strokes.

At Elucid, we focus on enabling efficient and transparent clinical insights to help usher in the next generation of CCTA-guided, personalized coronary artery disease care. We develop AI tools to see invisible features of risk and guide personalized, precise treatment based on a detailed analysis of patients’ atherosclerotic disease. Elucid’s platform transforms CT images into a dynamic, interactive map of disease, providing a more precise view of atherosclerosis – the root cause of cardiovascular disease – to help physicians personalize care based on a patient’s individual anatomy.

A smiling couple walks arm-in-arm through a vibrant outdoor market full of fresh vegetables and flowers.

Elucid Leadership

Andrew Miller Chief Technology Officer & SVP, Engineering

Andrew Miller

Chief Technology Officer & SVP, Engineering
Windi Hary Chief Regulatory & Quality Officer

Windi Hary

Chief Regulatory & Quality Officer
Amy Kruglak SVP, People & Leadership Development

Amy Kruglak

SVP, People & Leadership Development
Amir Ahmadi, MD Lead Scientific Advisor

Amir Ahmadi, MD

Lead Scientific Advisor

News, Media & Thought Leadership

Stay informed with the latest updates, insights, and conversations from Elucid.
Type
Elucid announces first patient enrollment in the AI-PREDICT study for cardiovascular risk assessment.

Elucid Announces First Patient Enrollment in AI-PREDICT, a Landmark International Study to Define Lesion-Level Cardiovascular Risk

Elucid, an innovator in AI-powered coronary CT angiography (CCTA) analysis, today announced first patient enrollment in AI-PREDICT, a retrospective, international, multicenter study designed to establish a new lesion-centric paradigm for cardiovascular risk stratification.
Medical imaging scans and text about Elucid presenting CCTA vision for personalized cardiac care at SCCT 2026.

Elucid to Showcase CCTA Vision at SCCT 2026, Defining the Future of Personalized Cardiovascular Care

Elucid, an innovator in AI-powered coronary CT angiography (CCTA) analysis, today announced its largest and most comprehensive presence to date at the Society of Cardiovascular Computed Tomography Annual Scientific Meeting (SCCT 2026), taking place July 9 - 12, 2026, at the Gaylord Pacific Resort & Convention Center in Chula Vista, Calif.
Screenshot of Elucid’s software with text announcing its 2026 MedTech Breakthrough Award for cardiology tech.

Elucid’s Plaque-IQ™ Named “Best New Cardiology Technology Solution” in 2026 MedTech Breakthrough Awards Program

Elucid today announced that its Plaque-IQ arterial plaque analysis software has been selected as winner of the “Best New Cardiology Technology Solution” award in the 10th annual MedTech Breakthrough Awards.
Computer screen showing Elucids lesion inspection tool for artery plaque analysis, with medical images displayed.

Elucid Announces Commercial Availability of Lesion Inspection Tool for Plaque-IQ™

Elucid announced today the commercial availability of a new Lesion Inspection Tool for coronary and carotid plaque analysis in its novel Plaque-IQ software suite.
Blue graphic announcing broad reimbursement for Plaque-IQ™, with text and a carotid artery illustration on right.

Elucid Announces Broad Reimbursement for Quantitative Coronary Plaque Analysis

Effective January 1, 2026, its Plaque-IQ™ coronary plaque analysis has received a new Category I Current Procedural Terminology (CPT®) designation, alongside increasingly widespread coverage and reimbursement from both public and private payors. Together, these developments underscore the clinical value of coronary plaque analysis and establish favorable conditions for broader adoption of the technology.
Curved modern building with many windows, set against a clear blue sky with a small white cloud.

Where to Find Us: Upcoming Events

Washington Hilton – Washington, DC – March 7-10, 2026

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Stay in Touch

Subscribe to our newsletter for the latest clinical, product and regulatory updates.

Eight people in an office sit and stand together, smiling and making heart shapes with their hands.